vimarsana.com
Home
Live Updates
Nordic Nanovector to Conduct a Comprehensive Review and Inde
Nordic Nanovector to Conduct a Comprehensive Review and Inde
Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin in R/R FL as a Result of Continuing Slow Recruitment
OSLO, Norway, June 2, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its ongoing Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) in
Related Keywords
Norway ,
Norwegian ,
Malene Brondberg ,
Frazer Hall Medi ,
,
Nordic Nanovector ,
Independent Expect ,
Frazer Hall ,
Norwegian Securities Trading ,
Nordic ,
Nanovector ,
Conduct ,
Comprehensive ,
Review ,
Independent ,
Data ,
Evaluation ,
Paradigme ,
Hase ,
Trial ,
Etalutin ,
Result ,
Continuing ,
Low ,
Recruitment ,